These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18509671)

  • 21. Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants.
    Fanzani A; Stoppani E; Gualandi L; Giuliani R; Galbiati F; Rossi S; Fra A; Preti A; Marchesini S
    FEBS Lett; 2007 Oct; 581(26):5099-104. PubMed ID: 17935719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
    Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
    J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membrane cholesterol modulates dihydropyridine receptor function in mice fetal skeletal muscle cells.
    Pouvreau S; Berthier C; Blaineau S; Amsellem J; Coronado R; Strube C
    J Physiol; 2004 Mar; 555(Pt 2):365-81. PubMed ID: 14724204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.
    Sotgia F; Woodman SE; Bonuccelli G; Capozza F; Minetti C; Scherer PE; Lisanti MP
    Am J Physiol Cell Physiol; 2003 Nov; 285(5):C1150-60. PubMed ID: 12839838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two novel CAV3 gene mutations in Japanese families.
    Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I
    Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.
    Volonte D; Peoples AJ; Galbiati F
    Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
    Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane.
    Kerr JP; Ziman AP; Mueller AL; Muriel JM; Kleinhans-Welte E; Gumerson JD; Vogel SS; Ward CW; Roche JA; Bloch RJ
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20831-6. PubMed ID: 24302765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveolin-3 regulates the activity of Ca
    Matsunobe M; Motohashi N; Aoki E; Tominari T; Inada M; Aoki Y
    Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1137-C1148. PubMed ID: 35993515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular localization of dysferlin and its association with the dihydropyridine receptor.
    Ampong BN; Imamura M; Matsumiya T; Yoshida M; Takeda S
    Acta Myol; 2005 Oct; 24(2):134-44. PubMed ID: 16550931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of calcium permeation in dihydropyridine receptor function. Insights into channel gating and excitation-contraction coupling.
    Dirksen RT; Beam KG
    J Gen Physiol; 1999 Sep; 114(3):393-403. PubMed ID: 10469729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities.
    Galbiati F; Engelman JA; Volonte D; Zhang XL; Minetti C; Li M; Hou H; Kneitz B; Edelmann W; Lisanti MP
    J Biol Chem; 2001 Jun; 276(24):21425-33. PubMed ID: 11259414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3.
    Hernández-Deviez DJ; Martin S; Laval SH; Lo HP; Cooper ST; North KN; Bushby K; Parton RG
    Hum Mol Genet; 2006 Jan; 15(1):129-42. PubMed ID: 16319126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.
    Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP
    J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caveolinopathies: from the biology of caveolin-3 to human diseases.
    Gazzerro E; Sotgia F; Bruno C; Lisanti MP; Minetti C
    Eur J Hum Genet; 2010 Feb; 18(2):137-45. PubMed ID: 19584897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
    Cai C; Weisleder N; Ko JK; Komazaki S; Sunada Y; Nishi M; Takeshima H; Ma J
    J Biol Chem; 2009 Jun; 284(23):15894-902. PubMed ID: 19380584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability.
    Campostrini G; Bonzanni M; Lissoni A; Bazzini C; Milanesi R; Vezzoli E; Francolini M; Baruscotti M; Bucchi A; Rivolta I; Fantini M; Severi S; Cappato R; Crotti L; J Schwartz P; DiFrancesco D; Barbuti A
    Cardiovasc Res; 2017 Aug; 113(10):1256-1265. PubMed ID: 28898996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a multiprotein complex involved in excitation-transcription coupling of skeletal muscle.
    Arias-Calderón M; Almarza G; Díaz-Vegas A; Contreras-Ferrat A; Valladares D; Casas M; Toledo H; Jaimovich E; Buvinic S
    Skelet Muscle; 2016; 6():15. PubMed ID: 27069569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the molecular architecture of human caveolin-3 and interaction with the skeletal muscle ryanodine receptor.
    Whiteley G; Collins RF; Kitmitto A
    J Biol Chem; 2012 Nov; 287(48):40302-16. PubMed ID: 23071107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A CAV3 microdeletion differentially affects skeletal muscle and myocardium.
    Cagliani R; Bresolin N; Prelle A; Gallanti A; Fortunato F; Sironi M; Ciscato P; Fagiolari G; Bonato S; Galbiati S; Corti S; Lamperti C; Moggio M; Comi GP
    Neurology; 2003 Dec; 61(11):1513-9. PubMed ID: 14663034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.